- Home
- GFR vs MREO Comparison
GFR vs MREO Comparison
Compare GFR & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GFR
- MREO
- Stock Information
- Founded
- GFR 2018
- MREO 2015
- Country
- GFR Canada
- MREO United Kingdom
- Employees
- GFR N/A
- MREO N/A
- Industry
- GFR
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- GFR
- MREO Health Care
- Exchange
- GFR Nasdaq
- MREO Nasdaq
- Market Cap
- GFR 330.9M
- MREO 326.1M
- IPO Year
- GFR N/A
- MREO N/A
- Fundamental
- Price
- GFR $4.72
- MREO $2.04
- Analyst Decision
- GFR
- MREO Strong Buy
- Analyst Count
- GFR 0
- MREO 5
- Target Price
- GFR N/A
- MREO $7.40
- AVG Volume (30 Days)
- GFR 40.3K
- MREO 1.3M
- Earning Date
- GFR 11-13-2025
- MREO 11-11-2025
- Dividend Yield
- GFR N/A
- MREO N/A
- EPS Growth
- GFR N/A
- MREO N/A
- EPS
- GFR 2.05
- MREO N/A
- Revenue
- GFR $516,308,125.00
- MREO $500,000.00
- Revenue This Year
- GFR N/A
- MREO N/A
- Revenue Next Year
- GFR $27.03
- MREO $72.16
- P/E Ratio
- GFR $2.31
- MREO N/A
- Revenue Growth
- GFR N/A
- MREO N/A
- 52 Week Low
- GFR $3.81
- MREO $1.47
- 52 Week High
- GFR $8.16
- MREO $4.72
- Technical
- Relative Strength Index (RSI)
- GFR 46.29
- MREO 66.10
- Support Level
- GFR $4.54
- MREO $1.94
- Resistance Level
- GFR $5.07
- MREO $2.11
- Average True Range (ATR)
- GFR 0.21
- MREO 0.11
- MACD
- GFR -0.05
- MREO 0.03
- Stochastic Oscillator
- GFR 23.44
- MREO 80.72
About GFR Greenfire Resources Ltd.
Greenfire Resources Ltd explores, acquires, develops and produces oil and gas in the Canadian energy sector and internationally. Greenfire currently has two producing oil sand assets, Hangingstone Expansion and Hangingstone Demo. The Company has one reportable operating segment which is made up of its oil sands operations based on geographic location : Athabasca oil sands region of Alberta, Canada, nature of the products sold and integration of facilities and operations.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).